MediGene

MediGene AG is a Germany-based biotechnology company focused on the development of innovative T cell receptor (TCR)-guided immunotherapies for cancer treatment. The company applies advanced immuno-oncology research to create precise and scalable cell-based therapies for patients with solid tumors.

Core Expertise

• T cell receptor (TCR) discovery and validation
• Development of TCR-based cell therapies
• Immuno-oncology solutions for solid tumors
• Translational research from discovery to clinical stages

Technology Platform

MediGene operates a proprietary End-to-End TCR Platform designed to identify highly specific T cell receptors with improved tumor targeting and reduced off-target risk. The platform supports both personalized and scalable therapeutic approaches in immuno-oncology.

Pipeline Summary

Partnerships and Collaboration

MediGene collaborates with international biotechnology and pharmaceutical companies as well as academic research institutions to accelerate development and expand the therapeutic potential of its TCR-based technologies.

• BioNTech
• 2seventy bio
• WuXi Biologics
• Academic research partners

With decades of experience in immuno-oncology and a strong focus on TCR innovation, MediGene AG aims to advance next-generation cancer immunotherapies that improve treatment precision and patient outcomes.